China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has formed a strategic partnership with fellow Chinese firm Shaanxi Lifegen Co. Ltd. The collaboration aims to deepen efforts in platform construction, sequencing, and full product development, although financial details of the partnership were not disclosed.
Scope of the Partnership
The partnership will encompass a broad spectrum of activities, including technology research and development, translational research, and talent cultivation. By pooling resources and expertise, Sansure Biotech and Shaanxi Lifegen intend to address clinical medical diagnosis and treatment challenges, as well as unmet needs, thereby enhancing clinical precision diagnosis and treatment capabilities.
Focus Areas and Objectives
Utilizing advanced molecular diagnostic technologies such as high-throughput sequencing, the two companies will concentrate on key areas including the prevention and control of respiratory infections, infectious disease management, personalized medication for malignant tumors, birth defect interventions, early tumor screening, emergency and critical care, severe infection control, chronic disease management, and the construction of biological sample banks.
Building a Cooperative Platform
A central goal of the partnership is to jointly establish a robust cooperation platform that fosters collaboration across industry, academia, and research applications. This integrated approach is designed to accelerate innovation and improve public health outcomes through more precise and effective diagnostic and treatment solutions.-Fineline Info & Tech
